Manish R. Patel

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text

Medicine, Hematology, Oncology +13

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Manish R. Patel, John Ellerton, Jeffrey R. Infante et al. · The Lancet Oncology · 2017 · 588 citations · Full text

Medicine, Oncology, Urology +12

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian et al. · Journal of Clinical Oncology · 2017 · 582 citations

Medicine, Oncology, Pharmacology +17

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 468 citations · Full text

Medicine, Molecular Biology, Oncology +13

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 454 citations · Full text

Medicine, Oncology, Pharmacology +12